Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism MLL1 inhibitors(lysine methyltransferase 2A inhibitors), WDR5 inhibitors(WD repeat-containing protein 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC28H44N8O5 |
InChIKeyZAIPJVQTYUSDTG-LDFBIXNTSA-N |
CAS Registry2097887-20-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leukemia | Preclinical | US | 12 Jun 2017 |